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Abstract 14 
This review introduces a new hypothesis: that sympathetically mediated hypertensive 15 
diseases are caused, in most part, by the activation of visceral afferent systems that are 16 
connected to neural circuits generating sympathetic activity. We consider how organ 17 
hypoperfusion and blood flow supply-demand mismatch might lead to both sensory 18 
hyper-reflexia and aberrant afferent tonicity. We discuss how this may drive sympatho-19 
excitatory positive feedback and extend across multiple organs initiating, or at least 20 
amplifying sympathetic hyperactivity. The latter, in turn, compounds the challenge to 21 
sufficient organ blood flow through heightened vasoconstriction that both maintains and 22 
exacerbates hypertension.   23 
 24 
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28 
Overview 29 
Causes of elevated sympathetic activity in neurogenic hypertension remain enigmatic.  30 
We explore evidence to support the notion of blood flow supply-demand mismatch to an 31 
organ as a factor involved in the initiation of raised sympathetic activity, and its 32 
subsequent amplification, in hypertension. We first consider some homeostatic 33 
mechanisms regulating blood flow and then discuss emerging changes that may occur 34 
during the development of hypertension that sensitize afferent innervation of target 35 
organs. We hypothesize that activation of visceral afferent systems induces increases in 36 
sympathetic nerve activity (SNA) that can initiate and sustain hypertension. We term this, 37 
the visceral afferent activation hypothesis of hypertension.  38 
 39 
Physiological mechanisms ensuring organ blood flow homeostasis: a brief 40 
overview 41 
All organs have a capacity to increase blood flow through local functional (reactive) 42 
hyperaemia, autoregulatory, endocrine and neural mechanisms. Blood flow 43 
autoregulation is defined as the ability of an organ to maintain a constant blood flow 44 
despite either increases or decreases in blood (perfusion) pressure. Blood flow 45 
autoregulation is intrinsic to the arterioles within the organ and occurs in the absence of 46 
neural and hormonal influences. Endocrine controls include epinephrine and 47 
norepinephrine, as well as vasopressin, the renin-angiotensin-aldosterone system 48 
(RAAS), atrial natriuretic peptide, and erythropoietin. Neural mechanisms include 49 
baroreceptors in the aorta, carotid sinuses and right atrium, and peripheral and central 50 
chemoreceptors that monitor blood levels of oxygen, carbon dioxide, and hydrogen ions; 51 
together these systems modulate levels of autonomic and hormonal activity through 52 
central reflex arcs coursing through various inter-connected central nervous system 53 
structures. Such structures also bring about blood flow homeostasis during stress, 54 
hyperosmolarity, emotion, fear and anxiety. In physiological conditions, the 55 
aforementioned homeostatic mechanisms will distribute blood flow, and hence  oxygen, 56 
to organs in proportion to their metabolic demand, which is precisely controlled [1]. 57 
Normally, oxygen delivery exceeds the rate of oxygen consumption (demand) 58 
safeguarding capacity within each organ, which can be tapped into as a change in state 59 
demands [1]. For example, upon ascending to high altitude or during exercise, blood flow 60 
is increased to maintain a preferred supply/demand ratio [1]. However, if demand 61 
outstrips supply (i.e. a blood flow supply-demand mismatch), then hypoxic-hypoperfusion 62 
results. This might be corrected by increasing perfusion pressure, perhaps evoked 63 
through excitation of the organ’s own afferent system. However, according to Poiseuille’s 64 
law, at constant perfusion pressure blood flow is directly proportional to the fourth power 65 
of the radius of the vessel, meaning that a proportionally large increase in blood pressure 66 
will be needed to restore blood flow if the radius decreases i.e. the resistance increases.  67 
Blood pressure can be elevated by increasing either cardiac output and/or vascular 68 
resistance through activation of a neurohumoral mechanism including vasomotor 69 
sympathetic activity. Once the organ oxygen demand returns to basal levels, 70 
haemodynamic homeostasis is restored. However, if organ hypoxic hypoperfusion 71 
persists, or if the afferent circuits from that organ convey signals of such condition, even 72 
if aberrantly once it has passed, we surmise that this may result in augmented 73 
sympathetic discharge and thus hypertension. It has been maintained that most forms of 74 
hypertension are associated with increased total peripheral resistance (TPR), rather than 75 
increased cardiac output [2].  In such conditions, increased SNA in both men and older 76 
women is a primary driver of increased TPR [3]. Chronic elevation of TPR as a 77 
mechanism to increase blood pressure may reduce organ blood flow capacity thereby 78 
increasing the vulnerability to tissue hypoxic-hypoperfusion. Since all organs are 79 
innervated by sensory nerves, we propose that organ hypoperfusion will activate afferent 80 
activity and reflexivelyreflexly stimulate sympathetic hyperactivity leading to hypertension. 81 
However, this generalised vasoconstriction may compromise blood flow to other organs 82 
and thus trigger blood flow a broad supply-demand mismatch, which may result in the 83 
recruitment of additional afferent drivers that compound the hypertensive state. We 84 
explore this cycle of maladaptation in more detail giving examples to substantiate this 85 
notion. 86 
   87 
The sympathetic problem of hypertension 88 
Unequivocal evidence supports chronic activation of the sympathetic nervous system as 89 
a characteristic of hypertension and its participation in the initiation, maintenance and 90 
progression of blood pressure in experimental animal and human studies [4]. A big clinical 91 
challenge is to unveil the cause(s) of sympathetic over-activation and design novel 92 
therapies that lower it below its threshold for triggering significant increases in TPR. 93 
Evidently, sympathetic hyperactivity interacts with many pathologies beyond neurogenic 94 
hypertension, including heart failure, salt sensitivity, obesity, glucose intolerance, 95 
rheumatoid arthritis and many more. However, the aim of our review is to understand the 96 
relationship between organ hypoperfusion and subsequent visceral afferent activation as 97 
a potential driver of sympathetically mediated hypertension. 98 
 99 
Visceral afferent hyperactivity: consequences for sympathetic activity and organ 100 
blood flow  101 
To the best of our knowledge, all organs are connected to the brain reciprocally by visceral 102 
afferent and efferent nerves (Fig. 1). Many of these afferent nerves can trigger sympatho-103 
excitatory responses through spinal and supra-spinal reflexes. Exceptions include 104 
baroreceptors, right atrial and pulmonary stretch receptors and some renal afferents that 105 
inhibit sympathetic activity and may oppose hypertension-induced sympathetic 106 
hyperactivity [5]. Interestingly, these receptors are mechanosensory and de-activated by 107 
hypoperfusion and/or metabolic stimuli so may not be relevant to blood flow supply-108 
demand mismatch [5].  We propose that metabolite-sensitive afferents (metabosensors) 109 
that trigger sympathetic activity responses are less susceptible to de-sensitisation 110 
(adaptation) and, under pathophysiological conditions, can: (i) become sensitized, 111 
producing exaggerated reflex responses (hyperreflexia) and, (ii) generate aberrant tone 112 
(hypertonicity); the latter has the potential to provide a sustained drive for maintaining 113 
high levels of sympathetic activity (Fig. 1). Their activation may actively depress 114 
sympatho-inhibitory reflexes, such as the arterial baroreceptor reflex. Evidence 115 
supporting the presence of excessive afferent signalling in hypertension comes from the 116 
kidney [6,7] and carotid body [8-11] as their selective denervation can reduce both 117 
sympathetic activity and blood pressure, as we discuss later.  118 
 119 
It is important to recognise that physiological afferent signalling from an organ may occur 120 
in response to stimulants released locally because of a change in metabolic demand. 121 
Such examples include: reduced blood flow and hypoxia, hypercapnia, and metabolic 122 
stress. Functional or reactive hyperaemia in skeletal muscle is a mechanism that equates 123 
the change in metabolic demand with increases in blood flow. The metabolites leached 124 
from respiring tissues cause localized vasodilatation but, at sufficient concentration, also 125 
stimulate afferent endings (group III or IV fibers). The latter results in reflex increases in 126 
sympathetic activity and arterial pressure, with the sole aim of increasing perfusion to the 127 
muscle bed from which the afferents were activated. Functional hyperaemia normally off-128 
sets sympathetically mediated vasoconstriction [12]. The net result is elevated blood flow 129 
to the metabolically active organ to satiate its increased demand for oxygen. The 130 
increased perfusion also serves to washout metabolites, reduce their accumulation and 131 
may temper afferent activity to a level that optimises oxygen supply and demand; hence 132 
an optimal equilibrium is reached. Afferent signalling normally ceases once oxygen supply 133 
outstrips demand. However, in disease states such as hypertension, afferent signalling 134 
may become exaggerated and persist even in the absence of metabolites. Further, local 135 
metabolites mediating the vasodilatation may be less effective at opposing high levels of 136 
sympathetically mediated vasoconstriction [13] [14]. Indeed, in hypertension, nitric oxide 137 
did not attenuate sympathetic vasoconstriction during exercise; an effect seen in animals 138 
with normal blood pressure [13]. We discuss these possibilities below. 139 
 140 
Sensitisation of afferent feedback generating sympathetic excess in hypertension 141 
Sympathetic activation patterns may be graded and/or differentially controlled on an 142 
organ basis. For example, the classic ‘defence’ or ‘alerting’ response is characterized by 143 
increases in arterial pressure and heart rate with vasodilatation in skeletal muscle 144 
(mediated, in part, by sympatho-inhibition), and vasoconstriction in the splanchnic, renal 145 
and cutaneous vascular beds  [15]. Our notion is that in conditions of hypertension there 146 
is an underlying imbalance, with vasodilatory metabolites giving way to a predominance 147 
of sympathetic vasoconstrictor influence that is driven by afferent sensitization and 148 
emergence of aberrant afferent tonicity. The mechanism(s) involved in afferent 149 
sensitisation and tone generation remain an open question and may be organ- and state-150 
dependent but could result as a consequence of hypoxic-hypoperfusion triggering 151 
transcriptional processes. We propose that a plethora of initiators/mediators could be 152 
involved in this sensitisation, including metabolic stressors (hypoxia, hypercapnia, 153 
hyperglycemia, ATP, potassium ions, low pH), oxidative stress, anatomical anomalies 154 
(preconditioned, congenital), anaemia, respiratory stress, atherosclerotic plaque, 155 
inflammation and RAS activation. These mediator(s) themselves may sensitise the very 156 
mechanisms that cause depolarisation and trigger receptor potentials in afferent endings 157 
resulting in a chronic excitatory effect. Important to our hypothesis is that aberrant afferent 158 
firing persists at rest in the absence of any metabolic stimuli, and thus is a pathological 159 
signal. The latter is highly relevant as at rest there will be an absence of opposing 160 
vasodilatory metabolites making sympathetically mediated vasoconstriction more 161 
intense, worsening the problems of hypoperfusion and hypertension. Through a vicious 162 
circle the latter would result in further stimulation of afferent activity and reflexivelyreflexly 163 
evoked sympathetic vasoconstriction accentuating the problem of blood flow supply-164 
demand mismatch. We do not rule out a cross-talk mechanism whereby sympathetic 165 
activity itself sensitises adjacent afferent endings as an additional amplifying mechanism; 166 
there is at least anatomical evidence for this in the kidney where afferents and 167 
sympathetic fibres are intertwined [16]. Highly analogous is somatosensory sensitization 168 
seen in states of “sympathetically-maintained pain” or reflex sympathetic dystrophy, now 169 
thought of as “complex regional pain syndrome”. These are chronic pain conditions 170 
associated with sympathetic sprouting onto primary afferents terminals, dorsal root 171 
ganglion and spinal dorsal horn afferent terminals [17]. Being released by sympathetic 172 
postganglionic neurones, ATP participates in this sensitisation [18]. We propose that the 173 
same process of sensitization may apply to visceral afferent activation of hypertension. 174 
 175 
Heightened activation of the sympathetic nervous system through aberrant afferent 176 
tonicity from an organ may offset the vasodilatation produced by functional hyperaemia. 177 
For example, abnormal muscle afferent signalling in heart failure patients increased the 178 
passive leg movement-induced increases in norepinephrine spillover and arterial blood 179 
pressure, which significantly reduced femoral blood flow, oxygen delivery, and tissue 180 
oxygen saturation [19]. If sympathetically mediated vasoconstriction becomes 181 
widespread across vascular beds this may recruit multiple sympatho-excitatory afferent 182 
systems and amplify the problem of raised blood pressure (Fig. 1). Additionally, 183 
autoregulation in response to the rising perfusion pressure will also increase vascular 184 
resistance in an attempt to maintain constant blood flow but at the expense of further 185 
elevating TPR. Moreover, persistent and heightened sympathetic activity may reset 186 
autoregulation to higher pressure levels (e.g. renal blood flow autoregulation curve is 187 
shifted to a higher range of renal arterial pressures in hypertensive dogs with enhanced 188 
sympathetic activity [20]) as well as cause arteriolar re-modelling[21]; this would have 189 
deleterious consequences for blood flow supply-demand matching. Finally, it is also likely 190 
that hypoxic-hypoperfusion and reduced blood flow become greatly agonized at night 191 
when blood pressure normally dips [22]. In a constant state of sympathetic overactivity it 192 
is easy to see how nocturnal dipping is lost in conditions of hypertension [23]. Below we 193 
consider some examples of organs exhibiting excessive afferent activity and heightened 194 
SNA in hypertension.  195 
 196 
Potential sources of afferent hyperactivity 197 
Although it seems that many, if not all, organs affect blood pressure regulation we will 198 
focus within this review on the organs that we consider as exemplary of our hypothesis 199 
and where evidence exists supporting organ hypoperfusion and blood flow supply-200 
demand mismatch triggering dysfunctional afferent activity and reflexivelyreflexly driven 201 
sympathetic activity.  202 
 203 
(i) Kidney afferents and hypertension 204 
Renal afferent nerves primarily terminate peripherally in the renal pelvis and project to the 205 
spinal cord with onward transmission to the nucleus tractus solitarii (NTS), rostral 206 
ventrolateral medulla (RVLM), subfornical organ and paraventricular nucleus (PVN). 207 
There are single modality fibres (mechanoreceptors) that sense stretch of the pelvic wall 208 
causing sympatho-inhibition, chemo-sensitive receptors causing sympatho-activation, 209 
and multimodal fibres that sense both (reviewed in [24]). Neurally mediated responses 210 
occurring in one kidney as a result of interventions on the same or opposite kidney have 211 
been defined as reno-renal reflexes, which function to decrease renal efferent SNA to 212 
minimize sodium retention [25]. However, in ischemic/hypoxic kidneys and/or in the 213 
hypertensive state there is a reversal of the reno-renal reflex: stimulation of afferent 214 
nerves by ischemic metabolites such as adenosine, and/or by uremic toxins such as urea 215 
[26] enhances the sympatho-excitatory state, increases salt retention and blood pressure.  216 
This reversal of the reno-renal reflex is significant since afferent signals emanating from 217 
the kidney to the central nervous system have been strongly associated with the aetiology 218 
of hypertension. Indeed in experimental animal models of hypertension the removal of 219 
the afferents by either dorsal rhizotomy [7,27-29] or specific inhibition of afferent fibers by 220 
capsaicin treatment [6] have proven to be anti-hypertensive. Interestingly, Cowley et 221 
al [30] has demonstrated that the reduction of the blood flow to the medulla, a mildly 222 
hypoxic area of the kidney, leads to hypertension and renal injury when either a 223 
pharmacologically induced or a naturally occurring imbalance of the normal redox state. 224 
This support the concept of oxidative stress as an initiator/mediator involved in 225 
hypertension, potentially via hypoxia-hypoperfusion and afferent sensitization. Recent 226 
clinical trials have shown that blood pressure and SNA are both reduced after bilateral 227 
denervation (afferent and efferents) of the kidneys in some drug-resistant hypertensive 228 
patients [31-33], although the efficacy of this intervention is debated [34]. Recently, it has 229 
emerged that afferents are important for the hypertensive state in chronic kidney disease 230 
[35]. Future studies are needed to understand the mechanisms for renal afferent 231 
sensitisation and tonicity in hypertensive patients; putative stimulants are discussed 232 
below. Hypothetically, understanding the latter may provide an effective means to select 233 
patients most likely to respond to treatment (pharmacological or denervation). Taken 234 
together, these data emphasize the role of afferent signals emanating from the kidney in 235 
the generation of hypertension. 236 
 237 
In recent years, evidence has accumulated that kidney hypoxia plays a significant role in 238 
the pathogenies and progression of renal disease [36-39]. Even a small lesion in the 239 
kidney, resulting in an area(s) of ischaemia not necessarily affecting renal function, can 240 
cause hypertension, perhaps via afferent activation [40]. Renal hypoperfusion, ischaemia 241 
and hypoxia can all trigger afferent signalling to reflexivelyreflexly elevate sympathetic 242 
activity and arterial pressure. This has led to the prediction that renal hypoxia is not just 243 
a consequence of kidney disease, but rather a primary pathogenic event [36-38,41-47]. 244 
But what could be the initial trigger? Exogenous administration of angiotensin-II (AngII) 245 
can lead to hypoperfusion of post-glomerular peritubular capillaries, and subsequent 246 
hypoxia within the tubules and interstitial space [39] [48]. We propose that hypertensive 247 
kidney disease is driven by vicious loops of positive feedback, initiated by increased AngII 248 
triggered by hypoperfusion and accompanied by nephron loss, inflammation and 249 
diabetes. This results in oxidative stress and nitric oxide deficiency augmenting 250 
hypoperfusion and renal afferent signalling. Therefore, improving blood perfusion and 251 
thus oxygenation of the kidneys may reduce SNA and arterial pressure and improve renal 252 
function, thereby providing a novel future treatment strategy. This is supported by the 253 
findings that: (i) pharmacologically increasing renal oxygen consumption per se caused 254 
renal hypoxia, proteinuria [49] and eventually leads to renal injury [50] and, (ii) application 255 
of 100% oxygen to patients with chronic kidney disease reduced muscle SNA, whereas 256 
such an intervention did not affect muscle SNA in control patients [51]. This mismatch in 257 
renal oxygen demand and supply exemplifies how afferent driven sympatho-excitatory is 258 
a powerful stimulus for hypertension.   259 
 260 
(ii) Carotid Body afferents and hypertension 261 
Stimulation of the carotid body (CB), the dominant peripheral chemoreceptor, drives 262 
sympathetic tone through relatively direct signalling to the NTS, RVLM and PVN resulting 263 
in increased blood pressure [52,53]. In cardiovascular diseases, it appears that the CB 264 
generates aberrant afferent discharge [8,9]. Schultz et al. have clearly implicated a 265 
significant role of CB afferent drive in the sympathetic hyperactivity and breathing 266 
dysregulation in animal models of chronic heart failure (CHF) [54,55]. Blood flow to the 267 
CB is exceptionally high in relation to tissue mass in health [56] but in rabbits with pacing 268 
induced chronic heart failure this was reduced due to lowered cardiac output [55]. This 269 
might account for CB afferent tonicity. Given this, one might predict that lowering CB 270 
afferent drive should be therapeutically beneficial. As a proof of principle CB resection 271 
was performed in heart failure patients and partially corrected cardiac autonomic balance 272 
and cardiac baroreflex gain [10,11], and reduced muscle sympathetic activity. Moreover, 273 
the CB is an afferent source driving sympathetically mediated hypertension in the 274 
spontaneously hypertensive rat (SHR) [8,9]. Again CB chemoreceptors are tonically 275 
active in the SHR [8,9] and their dis-connection from the brain is antihypertensive, 276 
substantially reduces renal sympathetic activity, and improved both baroreflex and renal 277 
function [8,9]. Intriguingly, there was an additive blood pressure lowering effect when 278 
renal denervation was subsequently performed [9]. These data strongly support our 279 
hypothesis that organ hypoperfusion and blood flow supply-demand mismatch recruits 280 
additional sources of afferent drive across organs with each independently contributing 281 
to sympathetic excess and hypertension (Fig. 1).  282 
 283 
(iii) Skeletal muscle afferents and hypertension 284 
Sympathetic engagement during exercise is initiated, in part, by activation of thin fiber 285 
afferents arising from contracting skeletal muscle. In the case of lower limb muscles these 286 
project via the lumbar dorsal horn of the spinal cord and via supra-spinal circuits modulate 287 
cardiovascular and respiratory activity and their reflex control [57]. These afferents are 288 
mechanically (mechanoreceptor; type III sensory fibres) and/or metabolically sensitive 289 
(metaboreceptor; type IV fibres). During the onset of exercise these afferents become 290 
activated and evoke the ‘exercise pressor response’ consisting of rises in arterial 291 
pressure, heart rate, stroke volume, cardiac output, redistribution of blood flow to active 292 
skeletal muscle and hyperventilation [58]. What evidence exists that these afferents 293 
become tonically active in the hypertensive state? In hypertension, sensitisation of both 294 
mechanically and metabolically sensitive skeletal muscle afferents has been 295 
demonstrated [59,60]. Moreover, the exercise pressor response is augmented and 296 
associated with the development of hypertension [61]. In chronic heart failure this includes 297 
an increased sensitivity of type 3 fibres compared to type 4 and heightened P2X response 298 
[62]. Functional sympatholysis, the process whereby sympathetic vasoconstriction is 299 
offset by metabolites released from the exercising skeletal muscle, is impaired 300 
substantially in hypertension [63]; this results in reduced oxygenation and blood flow in 301 
exercising muscles of hypertensive individuals compromising their ability to exercise [63]. 302 
This, presumably, leads to persistent afferent activation and hyperreflexia producing 303 
exaggerated pressor responses during exercise but may also contribute to reduced 304 
exercise tolerance through fatigue and possibly pain.  305 
 306 
There are a wide range of molecules involved in the regulation of blood flow to skeletal 307 
muscle during exercise. One major example is adenosine triphosphate (ATP). ATP, a 308 
potent vasodilator, stimulates the formation of both nitric oxide and prostaglandins [64], 309 
which counteract local sympathetic vasoconstriction [65,66]. A further source of nitric 310 
oxide production is by mechanically induced signals, including shear stress activated 311 
endothelial nitric oxide synthase [67]. Recent studies have shown that oxidative stress 312 
further increases vasoconstriction in skeletal muscle in rats with induced hypertension 313 
[68-70], suggesting a reduction/absence of the opposing dilatatory influence of nitric 314 
oxide.  Taken together, this supports our hypothesis of organ hypoperfusion and blood 315 
flow supply-demand mismatch and afferent sensitisation from a relatively large vascular 316 
bed that can drive neurogenic hypertension (Fig. 1). 317 
 318 
(iv) Other contributing afferents and cross talk 319 
Stimulation of intestinal mechanoreceptors (stretch) or chemoreceptors activates 320 
splanchnic nerve afferents resulting in decreases in tissue blood flow in the splanchnic 321 
organs (duodenum, jejunum, pancreas, spleen, stomach and liver) and kidneys [71]. This 322 
is most likely to be mediated by the sympathetic nervous system since electrical 323 
stimulation of intestinal afferents increases sympathetic activity in the splanchnic bed [71]. 324 
On the other hand, sympatho-inhibition occurs following the ingestion of a meal. This can 325 
augment splanchnic blood flow by approximately 150% above baseline, postprandially 326 
[72]. In hypertensive subjects blood flow to the splanchnic vascular bed is reduced [72], 327 
while in obese, hypertensive Sprague–Dawley rats the postprandial sympatho-inhibition 328 
and vasodilator effects are abolished. Although this does not separate cause from 329 
consequence it does indicate a connection between splanchnic hypoperfusion, reduced 330 
sympatho-inhibition and hypertension.  331 
 332 
High blood pressure can induce vascular (arterial/arteriole) hypertrophy [73] as can the 333 
increase in sympathetic nervous activity that is associated with hypertension [74-76]. 334 
Lumen narrowing, stiffening and exacerbated responses to sympathetic nervous system 335 
stimulation may all contribute to elevations in vascular resistance and the hypertensive 336 
condition. However, there is also evidence that the arterial re-modelling can occur before 337 
the development of hypertension as a congenital mechanism in the spontaneously 338 
hypertensive rat (SHR) [77].   339 
 340 
Activation of hepatic afferent nerves causes a decrease in blood flow through the hepatic 341 
artery again mediated by sympathetic nerves [78]. Activation of spinal cardiac afferents 342 
also increases sympathetic activity within minutes [79] and impairs baroreflex control of 343 
renal sympathetic nerve activity in rats [79]. Conceptually this positive feedback can 344 
correct hypoperfusion of cardiac tissue thereby reducing the severity of ischemia and 345 
decreasing infarct-size in myocardial ischemia injury. As mentioned above, cross talk 346 
between sympathetic and afferent fibres could be a part of a potential mechanism for 347 
sensitisation and afferent aberrant discharge as noradrenaline can activate sensory 348 
receptors directly [16], and ATP is co-released with NA from sympathetic post-ganglionic 349 
efferents [80] and further activates C-fibers. Indeed, there is histological evidence of close 350 
coupling between efferent and afferent C-fibres in human skin [81] and Kopp et al. have 351 
shown that there is a close apposition of afferent and efferent nerves in the renal pelvis 352 
[16]. Finally, activation of the sympathetic supply to the carotid body causing 353 
vasoconstriction [82] could also account for its sensitisation and aberrant tone in 354 
hypertension. 355 
 356 
The selfish brain hypothesis of hypertension 357 
Cushing’s response is enunciated as a physiological nervous system response to 358 
increased intracranial pressure that results in Cushing's triad of increased blood pressure, 359 
irregular breathing, and a reduction of heart rate. Paton et al have proposed that the 360 
‘Cushing Mechanism’ is not just a ‘last ditch’ protection for critically ischaemic brain but 361 
‘a physiological mechanism …. and key regulator of blood pressure’ [83]. This is 362 
supported by the observation that that in humans high blood pressure levels correlate 363 
with increased vertebral artery resistance [83,84]. Thus, could perfusion of the brain be a 364 
determinant of the set point of arterial pressure and is brainstem hypoperfusion a 365 
contributing mechanism in neurogenic hypertension?  In support of this, increasing 366 
cerebral artery vascular resistance activates the sympathetic nervous system in rats [76]. 367 
Further, Cates et al have demonstrated that vertebral artery narrowing, increased 368 
vertebral artery resistance, a shift to anaerobic metabolism within the brainstem and an 369 
exaggerated sympatho-excitatory response to reduced cerebral perfusion all occur prior 370 
the onset of hypertension in spontaneous hypertensive rats [85]. Tissue oxygen levels in 371 
the spontaneously hypertensive rat were found to be 15 mmHg lower than in a 372 
normotensive rat at the same level of arterial pressure [86]. The transduction mechanism 373 
is unknown but could include a central detector of hypoxia, an “intra-cranial baroreceptor”, 374 
ion-channels sensitive to blood flow or shear stress, [85] and may involve ATP and 375 
lactate [86]. For example, both traumatic and non-traumatic brain injury can result in 376 
paroxysmal sympathetic hyperactivity and hypertension [87].  377 
 378 
Future perspective 379 
Although many hypertensive drugs have a degree of penetrance into the brain, targeting 380 
the central nervous system with drugs causes poorly tolerated side effects and triggers a 381 
major clinical challenge of poor patient compliance to medication. According to our 382 
hypothesis, we need to consider targets within the peripheral nervous system and identify 383 
those visceral afferents that have become sensitised and tonically activated in 384 
hypertension. Establishing the molecular mechanisms for this afferent tonicity would then 385 
allow selective drugs (that need not cross the blood brain barrier) to temper their aberrant 386 
discharge. An ideal treatment would be a drug that targets a defined organ with known 387 
aberrant activity and blocks this pathological signalling while preserving the physiological 388 
operation of the afferent system. For example, selective blockade of purinergic receptor 389 
subtype (P2X3) abolished chronic pathological cough but defensive coughing (such as 390 
that evoked following aspiration) was preserved [88]. Reducing organ hypoxic-391 
hypoperfusion and improving organ blood flow and oxygen reserve/capacity is another 392 
considered approach for treating hypertension. Experimental evidence shows that intra-393 
renal renin-angiotensin-system (RAS) is compartmentalized from the systemic RAS such 394 
that intrarenal angiotensin converting enzyme (ACE) is not adequately inhibited by 395 
plasma concentrations of ACE inhibition in currently used dosages [89]. Given that 396 
angiotensin II can cause renal hypoxia and hypertension (see above), RAS inhibition 397 
selectively within the kidney may ameliorate hypoxic-hypoperfusion and reduce 398 
sympathetic hyperactivity. Furthermore activation of hypoxia inducible factors (HIF-1α 399 
and HIF-2α) has been demonstrated to protect kidneys from hypoxia and progressive 400 
injury [90] by making the kidneys less sensitive to hypoxic-hypoperfusion. Notably, the 401 
efficacy of HIF activation appears to depend on when it is administered during 402 
hypertensive kidney disease [91] stressing the importance of timing relative to disease 403 
progression.  Taken together, we propose that organ blood flow supply-demand mismatch 404 
could be a target for treating the sympathetic hyperactivity in hypertension. The future 405 
challenge is to off-set arteriolar vasoconstriction, increase organ blood flow and replenish 406 
the blood flow and oxygen supply of specific bodily organs.   407 
  408 
Executive summary 409 
 In physiological conditions blood flow is distributed to all organs in proportion to local 410 
oxygen/energy demand. 411 
 Blood flow demand can outstrip supply bringing about hypoxic-hypoperfusion 412 
especially when vasodilatory mechanisms are compromised. 413 
 Aberrant afferent signalling from an organ may occur in response to hypoperfusion or 414 
unmet oxygen demand.  415 
 Afferent sensitisation can lead to excessive reflexivelyreflexly evoked sympathetic 416 
vasoconstriction, hypoxic-hypoperfusion and reduced blood flow that leads to further 417 
activation of afferent activity. 418 
 Recent clinical trials have shown anti-hypertensive potency of: i) bilateral renal nerve 419 
denervation in some drug-resistant hypertensive patients and ii) carotid body afferent 420 
denervation in heart failure patients. 421 
 Hypertension is associated with an exaggerated exercise pressor response and we 422 
propose sensitisation and aberrant discharge from skeletal muscle afferents contribute 423 
to excessive sympathetic activity. 424 
 The brain stem may detect blood flow directly thereby acting as a central nervous 425 
system determinant of the set point of vasomotor sympathetic tone and contribute to 426 
sympathetic excess in the hypertensive condition if it becomes hypoperfused. 427 
 We propose that organ blood flow supply-demand mismatch is a major source of 428 
visceral afferent drive and can extend across organs contributing to sympathetic 429 
excess and hypertension, a process that is exacerbated during nocturnal blood 430 
pressure dipping. 431 
References 432 
1. Wolff C. Colloid Supplementation during Induction of Anesthesia. Emergency 433 
Medicine, 1(2), 1000EMOJ1108 (2015). 434 
2. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. Heart, 435 
89(9), 1104-1109 (2003). 436 
3. Hart EC, Charkoudian N. Sympathetic neural regulation of blood pressure: 437 
influences of sex and aging. Physiology, 29(1), 8-15 (2014). 438 
4. Esler M, Lambert E, Schlaich M. Point: Chronic activation of the sympathetic 439 
nervous system is the dominant contributor to systemic hypertension. Journal of 440 
applied physiology, 109(6), 1996-1998; discussion 2016 (2010). 441 
5. Hines T, Toney GM, Mifflin SW. Responses of neurons in the nucleus tractus 442 
solitarius to stimulation of heart and lung receptors in the rat. Circulation research, 443 
74(6), 1188-1196 (1994). 444 
6. Foss JD, Wainford RD, Engeland WC, Fink GD, Osborn JW. A novel method of 445 
selective ablation of afferent renal nerves by periaxonal application of capsaicin. 446 
American journal of physiology. Regulatory, integrative and comparative 447 
physiology, 308(2), R112-122 (2015). 448 
* Describes an exciting new methodology to specificity abolish renal afferent activity. 449 
7. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in 450 
rats with chronic renal failure. Hypertension, 25(4 Pt 2), 878-882 (1995). 451 
** A classic paper on experimental renal denervation in hypertension and kidney disease. 452 
8. Abdala AP, McBryde FD, Marina N et al. Hypertension is critically dependent on 453 
the carotid body input in the spontaneously hypertensive rat. The Journal of 454 
physiology, 590(Pt 17), 4269-4277 (2012). 455 
* Outlines the role and possible of the carotid body in neurogenic hypertension. 456 
9. McBryde FD, Abdala AP, Hendy EB et al. The carotid body as a putative 457 
therapeutic target for the treatment of neurogenic hypertension. Nature 458 
communications, 4, 2395 (2013). 459 
** Outlines the role and possible therapeutic target of the carotid body in neurogenic 460 
hypertension. 461 
10. Niewinski P, Janczak D, Rucinski A et al. Carotid body removal for treatment of 462 
chronic systolic heart failure. International journal of cardiology, 168(3), 2506-2509 463 
(2013). 464 
11. Niewinski P, Janczak D, Rucinski A et al. Dissociation between blood pressure and 465 
heart rate response to hypoxia after bilateral carotid body removal in men with 466 
systolic heart failure. Experimental physiology, 99(3), 552-561 (2014). 467 
12. Joyner MJ, Casey DP. Regulation of increased blood flow (hyperemia) to muscles 468 
during exercise: a hierarchy of competing physiological needs. Physiological 469 
reviews, 95(2), 549-601 (2015). 470 
13. Zhao W, Swanson SA, Ye J et al. Reactive Oxygen Species Impair Sympathetic 471 
Vasoregulation in Skeletal Muscle in Angiotensin II-Dependent Hypertension. 472 
Hypertension,  (2006). 473 
14. Thomas GD. Functional sympatholysis in hypertension. Autonomic Neuroscience, 474 
188, 64-68 (2015). 475 
* Classic paper on neural control of kidney function. 476 
15. Hilton SM. Ways of viewing the central nervous control of the circulation--old and 477 
new. Brain research, 87(2-3), 213-219 (1975). 478 
16. Kopp UC, Cicha MZ, Smith LA, Mulder J, Hokfelt T. Renal sympathetic nerve 479 
activity modulates afferent renal nerve activity by PGE2-dependent activation of 480 
alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. American journal 481 
of physiology. Regulatory, integrative and comparative physiology, 293(4), R1561-482 
1572 (2007). 483 
17. Schlereth T, Drummond PD, Birklein F. Inflammation in CRPS: role of the 484 
sympathetic supply. Autonomic neuroscience : basic & clinical, 182, 102-107 485 
(2014). 486 
18. Ford AP. In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and 487 
afferent sensitization. Purinergic Signal, 8(Suppl 1), 3-26 (2012). 488 
19. Ives SJ, Amann M, Venturelli M et al. The Mechanoreflex and Hemodynamic 489 
Response to Passive Leg Movement in Heart Failure. Med Sci Sports Exerc,  490 
(2015). 491 
20. Iversen BM, Kvam FI, Matre K, Ofstad J. Resetting of renal blood autoregulation 492 
during acute blood pressure reduction in hypertensive rats. The American journal 493 
of physiology, 275(2 Pt 2), R343-349 (1998). 494 
21. Renna NF, de Las Heras N, Miatello RM. Pathophysiology of vascular remodeling 495 
in hypertension. Int J Hypertens, 2013, 808353 (2013). 496 
22. Koroboki E, Manios E, Psaltopoulou T et al. Circadian variation of blood pressure 497 
and heart rate in normotensives, white-coat, masked, treated and untreated 498 
hypertensives. Hellenic J Cardiol, 53(6), 432-438 (2012). 499 
23. Sherwood A, Steffen PR, Blumenthal JA, Kuhn C, Hinderliter AL. Nighttime blood 500 
pressure dipping: the role of the sympathetic nervous system. American journal of 501 
hypertension, 15(2 Pt 1), 111-118 (2002). 502 
24. Johns EJ, Kopp UC, DiBona GF. Neural control of renal function. Comprehensive 503 
Physiology, 1(2), 731-767 (2011). 504 
25. Kopp UC. Role of renal sensory nerves in physiological and pathophysiological 505 
conditions. American journal of physiology. Regulatory, integrative and 506 
comparative physiology, 308(2), R79-R95 (2015). 507 
26. Katholi RE. Renal nerves and hypertension: an update. Federation proceedings, 508 
44(13), 2846-2850 (1985). 509 
27. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior 510 
hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int, 51(3), 511 
722-727 (1997). 512 
28. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the 513 
progression of renal disease in the renal ablation model of chronic renal failure in 514 
the rat. Am J Kidney Dis, 26(5), 861-865 (1995). 515 
29. Kopp UC, Cicha MZ, Smith LA. Dietary sodium loading increases arterial pressure 516 
in afferent renal-denervated rats. Hypertension, 42(5), 968-973 (2003). 517 
30. Cowley AW, Jr., Abe M, Mori T, O'Connor PM, Ohsaki Y, Zheleznova NN. Reactive 518 
oxygen species as important determinants of medullary flow, sodium excretion, 519 
and hypertension. American journal of physiology. Renal physiology, 308(3), 520 
F179-197 (2015). 521 
31. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic 522 
denervation for resistant hypertension: a multicentre safety and proof-of-principle 523 
cohort study. Lancet, 373(9671), 1275-1281 (2009). 524 
32. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal 525 
sympathetic denervation in patients with treatment-resistant hypertension (The 526 
Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 376(9756), 1903-527 
1909). 528 
33. Schlaich MP, Hering D, Sobotka PA, Krum H, Esler MD. Renal denervation in 529 
human hypertension: mechanisms, current findings, and future prospects. Curr 530 
Hypertens Rep, 14(3), 247-253 (2012). 531 
* Important paper demonstrating renal hypoxia precedes renal pathology. 532 
34. Bhatt DL, Kandzari DE, O'Neill WW et al. A controlled trial of renal denervation for 533 
resistant hypertension. The New England journal of medicine, 370(15), 1393-1401 534 
(2014). 535 
35. Salman IM. Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a 536 
Comprehensive Review. Current hypertension reports, 17(8), 59 (2015). 537 
36. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, 538 
hypoxia response and the progression of chronic kidney disease. Am J Nephrol, 539 
28(6), 998-1006 (2008). 540 
37. Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia 541 
after reperfusion of the ischemic kidney. Mol Med, 14(7-8), 502-516 (2008). 542 
38. Tanaka T, Kato H, Kojima I et al. Hypoxia and expression of hypoxia-inducible 543 
factor in the aging kidney. J Gerontol A Biol Sci Med Sci, 61(8), 795-805 (2006). 544 
39. Manotham K, Tanaka T, Matsumoto M et al. Evidence of tubular hypoxia in the 545 
early phase in the remnant kidney model. Journal of the American Society of 546 
Nephrology : JASN, 15(5), 1277-1288 (2004). 547 
40. Campese VM. A new model of neurogenic hypertension caused by renal injury: 548 
pathophysiology and therapeutic implications. Clin Exp Nephrol, 7(3), 167-171 549 
(2003). 550 
41. Evans RG, Gardiner BS, Smith DW, O'Connor PM. Intrarenal oxygenation: unique 551 
challenges and the biophysical basis of homeostasis. American journal of 552 
physiology. Renal physiology, 295(5), F1259-1270 (2008). 553 
42. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway 554 
to end-stage renal failure. Journal of the American Society of Nephrology : JASN, 555 
17(1), 17-25 (2006). 556 
43. Evans RG, Ince C, Joles JA et al. Haemodynamic influences on kidney 557 
oxygenation: clinical implications of integrative physiology. Clinical and 558 
experimental pharmacology & physiology, 40(2), 106-122 (2013). 559 
44. Hansell P, Welch WJ, Blantz RC, Palm F. Determinants of kidney oxygen 560 
consumption and their relationship to tissue oxygen tension in diabetes and 561 
hypertension. Clinical and experimental pharmacology & physiology, 40(2), 123-562 
137 (2013). 563 
45. Singh P, Ricksten SE, Bragadottir G, Redfors B, Nordquist L. Renal oxygenation 564 
and haemodynamics in acute kidney injury and chronic kidney disease. Clin Exp 565 
Pharmacol Physiol, 40(2), 138-147 (2013). 566 
46. Liss P, Cox EF, Eckerbom P, Francis ST. Imaging of intrarenal haemodynamics 567 
and oxygen metabolism. Clin Exp Pharmacol Physiol, 40(2), 158-167 (2013). 568 
47. Nangaku M, Rosenberger C, Heyman SN, Eckardt KU. Regulation of hypoxia-569 
inducible factor in kidney disease. Clin Exp Pharmacol Physiol, 40(2), 148-157 570 
(2013). 571 
48. Kondo N, Kiyomoto H, Yamamoto T et al. Effects of calcium channel blockade on 572 
angiotensin II-induced peritubular ischemia in rats. J Pharmacol Exp Ther, 316(3), 573 
1047-1052 (2006). 574 
49. Friederich-Persson M, Persson P, Fasching A, Hansell P, Nordquist L, Palm F. 575 
Increased kidney metabolism as a pathway to kidney tissue hypoxia and damage: 576 
effects of triiodothyronine and dinitrophenol in normoglycemic rats. Adv Exp Med 577 
Biol, 789, 9-14 (2013). 578 
50. Friederich-Persson M, Thorn E, Hansell P, Nangaku M, Levin M, Palm F. Kidney 579 
Hypoxia, Attributable to Increased Oxygen Consumption, Induces Nephropathy 580 
Independently of Hyperglycemia and Oxidative Stress. Hypertension). 581 
51. Hering D, Zdrojewski Z, Krol E et al. Tonic chemoreflex activation contributes to 582 
the elevated muscle sympathetic nerve activity in patients with chronic renal 583 
failure. Journal of hypertension, 25(1), 157-161 (2007). 584 
52. Marshall JM. Peripheral chemoreceptors and cardiovascular regulation. 585 
Physiological reviews, 74(3), 543-594 (1994). 586 
53. Blessing WW, Yu Y, Nalivaiko E. Medullary projections of rabbit carotid sinus 587 
nerve. Brain research, 816(2), 405-410 (1999). 588 
54. Schultz HD, Marcus NJ, Del Rio R. Role of the carotid body in the pathophysiology 589 
of heart failure. Current hypertension reports, 15(4), 356-362 (2013). 590 
55. Ding Y, Li YL, Schultz HD. Role of blood flow in carotid body chemoreflex function 591 
in heart failure. The Journal of physiology, 589(Pt 1), 245-258 (2011). 592 
56. Barnett S, Mulligan E, Wagerle LC, Lahiri S. Measurement of carotid body blood 593 
flow in cats by use of radioactive microspheres. Journal of applied physiology, 594 
65(6), 2484-2489 (1988). 595 
57. Nobrega AC, O'Leary D, Silva BM, Marongiu E, Piepoli MF, Crisafulli A. Neural 596 
regulation of cardiovascular response to exercise: role of central command and 597 
peripheral afferents. BioMed research international, 2014, 478965 (2014). 598 
58. Li J, Xing J. Muscle afferent receptors engaged in augmented sympathetic 599 
responsiveness in peripheral artery disease. Frontiers in physiology, 3, 247 (2012). 600 
59. Fisher JP, Seifert T, Hartwich D, Young CN, Secher NH, Fadel PJ. Autonomic 601 
control of heart rate by metabolically sensitive skeletal muscle afferents in humans. 602 
The Journal of physiology, 588(Pt 7), 1117-1127 (2010). 603 
60. Li J, Sinoway LI. ATP stimulates chemically sensitive and sensitizes mechanically 604 
sensitive afferents. American journal of physiology. Heart and circulatory 605 
physiology, 283(6), H2636-2643 (2002). 606 
61. Berger A, Grossman E, Katz M et al. Exercise blood pressure and the risk for future 607 
hypertension among normotensive middle-aged adults. Journal of the American 608 
Heart Association, 4(4) (2015). 609 
62. Wang HJ, Li YL, Gao L, Zucker IH, Wang W. Alteration in skeletal muscle afferents 610 
in rats with chronic heart failure. The Journal of physiology, 588(Pt 24), 5033-5047 611 
(2010). 612 
63. Vongpatanasin W, Wang Z, Arbique D et al. Functional sympatholysis is impaired 613 
in hypertensive humans. The Journal of physiology, 589(Pt 5), 1209-1220 (2011). 614 
64. Mortensen SP, Saltin B. Regulation of the skeletal muscle blood flow in humans. 615 
Experimental physiology, 99(12), 1552-1558 (2014). 616 
65. Rosenmeier JB, Hansen J, Gonzalez-Alonso J. Circulating ATP-induced 617 
vasodilatation overrides sympathetic vasoconstrictor activity in human skeletal 618 
muscle. The Journal of physiology, 558(Pt 1), 351-365 (2004). 619 
66. Nishiyama A, Fujisawa Y, Fukui T et al. Role of nitric oxide in regional blood flow 620 
in angiotensin II-induced hypertensive rats. Hypertension research : official journal 621 
of the Japanese Society of Hypertension, 24(4), 421-427 (2001). 622 
67. Hellsten Y, Nyberg M, Jensen LG, Mortensen SP. Vasodilator interactions in 623 
skeletal muscle blood flow regulation. The Journal of physiology, 590(Pt 24), 6297-624 
6305 (2012). 625 
68. Koba S, Watanabe R, Kano N, Watanabe T. Oxidative stress exaggerates skeletal 626 
muscle contraction-evoked reflex sympathoexcitation in rats with hypertension 627 
induced by angiotensin II. American journal of physiology. Heart and circulatory 628 
physiology, 304(1), H142-153 (2013). 629 
69. Nishiyama A, Fukui T, Fujisawa Y et al. Systemic and Regional Hemodynamic 630 
Responses to Tempol in Angiotensin II-Infused Hypertensive Rats. Hypertension, 631 
37(1), 77-83 (2001). 632 
70. Zhao W, Swanson SA, Ye J et al. Reactive oxygen species impair sympathetic 633 
vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. 634 
Hypertension, 48(4), 637-643 (2006). 635 
71. Pan HL, Deal DD, Xu Z, Chen SR. Differential responses of regional sympathetic 636 
activity and blood flow to visceral afferent stimulation. American journal of 637 
physiology. Regulatory, integrative and comparative physiology, 280(6), R1781-638 
1789 (2001). 639 
72. Sartor DM. Sympathoinhibitory signals from the gut and obesity-related 640 
hypertension. Clinical autonomic research : official journal of the Clinical 641 
Autonomic Research Society, 23(1), 33-39 (2013). 642 
73. Prewitt RL, Rice DC, Dobrian AD. Adaptation of resistance arteries to increases in 643 
pressure. Microcirculation, 9(4), 295-304 (2002). 644 
74. Reid JL. Vascular reactivity, adrenergic mechanisms, and arteriolar resistance in 645 
hypertension. J Cardiovasc Pharmacol, 12 Suppl 3, S114-120 (1988). 646 
75. Mayhan WG, Werber AH, Heistad DD. Protection of cerebral vessels by 647 
sympathetic nerves and vascular hypertrophy. Circulation, 75(1 Pt 2), I107-112 648 
(1987). 649 
76. Baumbach GL, Heistad DD, Siems JE. Effect of sympathetic nerves on 650 
composition and distensibility of cerebral arterioles in rats. The Journal of 651 
physiology, 416, 123-140 (1989). 652 
77. Cates MJ, Steed PW, Abdala AP, Langton PD, Paton JF. Elevated vertebrobasilar 653 
artery resistance in neonatal spontaneously hypertensive rats. Journal of applied 654 
physiology, 111(1), 149-156 (2011). 655 
78. Jensen KJ, Alpini G, Glaser S. Hepatic nervous system and neurobiology of the 656 
liver. Comprehensive Physiology, 3(2), 655-665 (2013). 657 
79. Gao L, Zhu Z, Zucker IH, Wang W. Cardiac sympathetic afferent stimulation 658 
impairs baroreflex control of renal sympathetic nerve activity in rats. American 659 
journal of physiology. Heart and circulatory physiology, 286(5), H1706-1711 660 
(2004). 661 
80. Kennedy C. ATP as a cotransmitter in the autonomic nervous system. Autonomic 662 
neuroscience : basic & clinical, 191, 2-15 (2015). 663 
81. Gibbs GF, Drummond PD, Finch PM, Phillips JK. Unravelling the pathophysiology 664 
of complex regional pain syndrome: focus on sympathetically maintained pain. 665 
Clinical and experimental pharmacology & physiology, 35(7), 717-724 (2008). 666 
82. Schultz HD, Li YL, Ding Y. Arterial chemoreceptors and sympathetic nerve activity: 667 
implications for hypertension and heart failure. Hypertension, 50(1), 6-13 (2007). 668 
83. Paton JF, Dickinson CJ, Mitchell G. Harvey Cushing and the regulation of blood 669 
pressure in giraffe, rat and man: introducing 'Cushing's mechanism'. Experimental 670 
physiology, 94(1), 11-17 (2009). 671 
** Outlines the Cushing's mechanism hypothesis. 672 
84. Dickinson CJ, Thomson AD. A post mortem study of the main cerebral arteries 673 
with special reference to their possible role in blood pressure regulation. Clinical 674 
science, 19, 513-538 (1960). 675 
85. Cates MJ, Dickinson CJ, Hart EC, Paton JF. Neurogenic hypertension and 676 
elevated vertebrobasilar arterial resistance: is there a causative link? Current 677 
hypertension reports, 14(3), 261-269 (2012). 678 
86. Marina N, Ang R, Machhada A et al. Brainstem hypoxia contributes to the 679 
development of hypertension in the spontaneously hypertensive rat. Hypertension, 680 
65(4), 775-783 (2015). 681 
87. Baguley IJ, Perkes IE, Fernandez-Ortega JF, Rabinstein AA, Dolce G, Hendricks 682 
HT. Paroxysmal sympathetic hyperactivity after acquired brain injury: consensus 683 
on conceptual definition, nomenclature, and diagnostic criteria. Journal of 684 
neurotrauma, 31(17), 1515-1520 (2014). 685 
88. Abdulqawi R, Dockry R, Holt K et al. P2X3 receptor antagonist (AF-219) in 686 
refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 687 
study. Lancet, 385(9974), 1198-1205 (2015). 688 
89. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of 689 
angiotensins I and II in anesthetized rats. Hypertension, 39(1), 129-134 (2002). 690 
90. Tanaka T, Nangaku M. Drug discovery for overcoming chronic kidney disease 691 
(CKD): prolyl-hydroxylase inhibitors to activate hypoxia-inducible factor (HIF) as a 692 
novel therapeutic approach in CKD. J Pharmacol Sci, 109(1), 24-31 (2009). 693 
91. Yu X, Fang Y, Liu H et al. The balance of beneficial and deleterious effects of 694 
hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant 695 
kidney depends on the timing of administration. Nephrol Dial Transplant, 27(8), 696 
3110-3119 (2012). 697 
 698 
Reference annotation: 699 
* Of interest 700 
** Of considerable interest 701 
Figure legend 702 
Figure 1. Schematic illustrating the visceral afferent activation hypothesis of 703 
hypertension.  704 
When afferents become sensitized due to, for example, high sympathetic activity, 705 
circulating angiotensin II, atheroma, or congenital predisposition (although exact 706 
mediator(s) remain to be identified) they reflexivelyreflexly increase sympathetic 707 
vasomotor tone reducing making an organ vulnerable to hypoxic-hypoperfusion and 708 
reducing its blood flow reserve/capacity. We propose that this triggers release of 709 
metabolites that activate excessive afferent nerve activity, which exacerbate the reflex-710 
evoked sympathetic vasoconstriction. Widespread sympathetic activation may recruit 711 
additional afferent systems resulting in additional drivers for maintaining pathologically 712 
high levels of sympathetic activity and total peripheral resistance. Thus, the system 713 
degenerates into a positive feedback loop in hypoxic-hypoperfusion and reduced blood 714 
flow reserve/capacity acts as an amplifier and conceivable initiator of sympathoexcitatory 715 
afferent drive. Consequently vasoconstriction, arteriole re-modelling increased total 716 
peripheral resistance and end organ damage will amplify the organ blood flow supply-717 
demand mismatch compounding the problem of hypoperfusion and the development and 718 
maintenance of hypertension. We do not rule out that excessive sympathetic activity itself 719 
sensitises the afferent nerves mediating the reflex-evoked sympatho-excitation. Artwork 720 
was provided by Michel Cekalovic (www.moviesandgraphics.com). 721 
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